Get the Stockscreener App
1.56
0.65%
0.01
After Hours:
1.57
0.01
+0.64%
Repare Therapeutics Inc stock is traded at $1.56, with a volume of 83,584.
It is up +0.65% in the last 24 hours and up +13.87% over the past month.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
See More
Previous Close:
$1.55
Open:
$1.56
24h Volume:
83,584
Relative Volume:
0.25
Market Cap:
$66.91M
Revenue:
$51.13M
Net Income/Loss:
$-93.80M
P/E Ratio:
-0.6996
EPS:
-2.23
Net Cash Flow:
$-129.10M
1W Performance:
+3.31%
1M Performance:
+13.87%
6M Performance:
+27.87%
1Y Performance:
-60.00%
1-Day Range:
$1.545
$1.58
1-Week Range:
$1.50
$1.58
52-Week Range:
$0.89
$4.22
Repare Therapeutics Inc Stock (RPTX) Company Profile
Name
Repare Therapeutics Inc
Sector
Industry
Phone
(857) 412-7018
Address
7171 FREDERICK BANTING, SAINT-LAURENT, QC
Compare RPTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPTX
Repare Therapeutics Inc
|
1.56 | 66.48M | 51.13M | -93.80M | -129.10M | -2.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-23 | Upgrade | Stifel | Hold → Buy |
| Feb-03-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-06-23 | Initiated | CapitalOne | Overweight |
| Apr-12-22 | Downgrade | Stifel | Buy → Hold |
| Mar-17-22 | Resumed | Goldman | Buy |
| Sep-23-21 | Initiated | Stifel | Buy |
| Sep-13-21 | Initiated | H.C. Wainwright | Buy |
| Jun-28-21 | Initiated | Guggenheim | Buy |
| Mar-01-21 | Initiated | Berenberg | Buy |
| Oct-28-20 | Initiated | Northland Capital | Outperform |
| Jul-14-20 | Initiated | Cowen | Outperform |
| Jul-14-20 | Initiated | Goldman | Neutral |
| Jul-14-20 | Initiated | Morgan Stanley | Overweight |
| Jul-14-20 | Initiated | Piper Sandler | Overweight |
View All
Repare Therapeutics Inc Stock (RPTX) Latest News
Repare Therapeutics (NASDAQ:RPTX) Trading 0.6% Higher – What’s Next? - Defense World
Repare Therapeutics (NASDAQ:RPTX) Trading 0.6% HigherWhat's Next? - MarketBeat
Is Repare Therapeutics Inc. a good long term investmentMassive portfolio appreciation - PrintWeekIndia
Will Repare Therapeutics Inc. stock benefit from interest rate changesExplosive earnings growth - jammulinksnews.com
Why Repare Therapeutics Inc. stock is on top investor watchlistsUnrivaled growth potential - jammulinksnews.com
What analysts say about Repare Therapeutics Inc. stock outlookMarket-leading growth rates - jammulinksnews.com
What drives Repare Therapeutics Inc. stock priceFree Wealth Planning Blueprint - Autocar Professional
What analysts say about Repare Therapeutics Inc. stockPowerful growth strategies - jammulinksnews.com
Why Repare Therapeutics Inc. stock attracts strong analyst attentionFree Access to Community - Newser
Repare Therapeutics Inc. Stock Analysis and ForecastUnprecedented growth rates - jammulinksnews.com
what makes repare therapeutics inc. stock price move sharplyLow Risk Profit Ideas - Newser
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
Repare Therapeutics Jumps 15% After $10M Licensing Deal With Debiopharm - Yahoo Finance
How Repare Therapeutics Inc. stock performs during market volatilityBig Profit Small Risk Alerts - Newser
Repare Therapeutics Jumps 15% After $10M Licensing Deal With Deb - GuruFocus
Repare Therapeutics Licenses Lunresertib to Debiopharm for Worldwide Development. - AInvest
Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab - insights.citeline.com
Repare inks licensing deal with Debiopharm for lunresertib - The Pharma Letter
Repare Therapeutics Jumps After Hours On $267M Global Licensing Deal With Debiopharm; Retail Traders Rush In - Stocktwits
how repare therapeutics inc. stock performs during market volatilityFast Moving Stock Alerts - Newser
Repare Therapeutics' Lunresertib Deal: A Strategic Pivot to Unlock Oncology Potential and Near-Term Catalysts - AInvest
Repare Therapeutics stock surges after $10M licensing deal with Debiopharm By Investing.com - Investing.com South Africa
What makes Repare Therapeutics Inc. stock price move sharplyHigh Reward Risk Balanced Trading - Newser
Repare Therapeutics stock surges after $10M licensing deal with Debiopharm - Investing.com Nigeria
Repare Therapeutics Inc. Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib - MarketScreener
Repare Therapeutics (RPTX) Secures Global Licensing Deal with Debiopharm | RPTX Stock News - GuruFocus
Repare Therapeutics enters exclusive worldwide licensing agreement with Debiopharm for Lunresertib - MarketScreener
Repare Therapeutics licenses PKMYT1 inhibitor to Debiopharm for $10 million - Investing.com Nigeria
Repare Therapeutics licenses PKMYT1 inhibitor to Debiopharm for $10 million By Investing.com - Investing.com South Africa
Repare Therapeutics jumps on cancer drug licensing deal - TradingView
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib | RPTX Stock News - GuruFocus
Repare Therapeutics Inc Stock (RPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):